Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment-Reference-Cited by-同舟云学术

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment

Published:2014-02 Issue:1 Volume:3 Page:67-75
ISSN:1758-1966
Container-title:Lung Cancer Management
language:en
Short-container-title:Lung Cancer Management

Author:

Cheng Haiying¹,Shcherba Marina²,Pendurti Gopichand²,Liang Yuanxin²,Piperdi Bilal²,Perez-Soler Roman²

Affiliation:

1. Montefiore Medical Center/Albert Einstein College of Medicine, Department of Oncology, 111 East 210th Street, NY 10467, USA.

2. Montefiore Medical Center/Albert Einstein College of Medicine, Department of Oncology, 111 East 210th Street, NY 10467, USA

Abstract

SUMMARY The PI3K/AKT/mTOR pathway is commonly activated in non-small-cell lung cancer. It plays important roles in promoting oncogenesis in lung cancer and mediating resistance to EGF receptor tyrosine kinase inhibitors. Targeted agents against the components of this pathway are currently in development and their clinical benefits remain to be defined. This review provides an overview of the pathway dysregulation and novel agents targeting the pathway in lung cancer. In addition, potential predictive biomarkers guiding patient selection for targeted PI3K/AKT/mTOR inhibition is also discussed.

Publisher

Future Medicine Ltd

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/lmt.13.72

Reference80 articles.

1. Cancer statistics, 2012

2. Chipping away at the lung cancer genome

3. Targeting PI3K signalling in cancer: opportunities, challenges and limitations

4. PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies

5. Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer

Cited by 109 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combined computational and synthetic strategies for the development of potent pyrazolo-pyridine derivatives as anticancer agents;Journal of Molecular Structure;2024-09

2. Ornidazole Inhibits the Angiogenesis and Migration Abilities of Non-small Cell Lung Cancer (NSCLC) via Downregulation of VEGFA/VEGFR2/NRP-1 and PI3K/AKT/mTOR Pathways;Cell Biochemistry and Biophysics;2024-06-17

3. Antibody nanoparticle conjugate–based targeted immunotherapy for non–small cell lung cancer;Science Advances;2024-06-14

4. Iridium(III) carbene complexes as potent girdin inhibitors against metastatic cancers;Proceedings of the National Academy of Sciences;2024-06-11

5. DCA: An Interpretable Deep Learning Model for Cancer Classification and New Knowledge Discovery Using Attention Mechanism with Discriminate Feature Constraint;Proceedings of the 2024 3rd International Symposium on Intelligent Unmanned Systems and Artificial Intelligence;2024-05-17